Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Relugolix

A list of these Relugolix articles makes it easy for you to quickly access relevant information. We have prepared the following professional Relugolix, hoping to help solve your questions and better understand the product information you care about.
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 27 2025

    2025-01-27

    This week, there are 10 drugs in the patent and exclusivity list. They are: - Myfembree by Sumitomo Pharma Switzerland, containing active ingredient Estradiol, Norethindrone Acetate, and Relugolix - Orgovyx by Sumitomo Pharma Switzerland, containing active ingredient Relugolix - Nulibry by Sentynl Therapeutics, containing active ingredient Fosdenopterin Hydrobromide - Delstrigo by Merck Sharp and Dohme, containing active ingredient Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate - Pifeltro by Merck Sharp and Dohme, containing active ingredient Doravirine - Geodon by Viatris Specialty, containing active ingredient Ziprasidone Hydrochloride - Reyvow by Eli Lilly, containing active ingredient Lasmiditan Succinate - Cabenuva Kit by ViiV Healthcare, containing active ingredient Cabotegravir and Rilpivirine - Vocabria by ViiV Healthcare, containing active ingredient Cabotegravir Sodium - Imbruvica by Pharmacyclics, containing active ingredient Ibrutinib Read More